**Available Dosage Forms**

- Omalizumab 75 mg / 0.5 mL injection solution in a single-dose prefilled syringe.

- Omalizumab 150 mg/mL injection solution in a single-dose prefilled syringe

- Omalizumab 150 mg lyophilized powder for reconstitution in a single-dose vial

- Generally, omalizumab dosing and frequency are determined by serum total IgE levels and the patient's body weight. In the United States, the total serum IgE should be in the range of 30 to 700 IU/ml, and in Europe for adults and children above the age of 12, the range is between 30 to 1500 IU/ml, while for children between 6 to 12, IgE levels should be under 1300 IU/ml.

**Asthma**

- The recommended dose for treatment of asthma is 75 mg - 375 mg by subcutaneous injection every two or four weeks.

- The basis for dose and frequency is calculated considering patient weight and pretreatment total IgE serum levels.

- There is no dosing adjustment based on total IgE levels taken during treatment.

- No dose adjustment is necessary for any significant weight changes

**Chronic Urticaria**

- Administer omalizumab 150 mg or 300 mg****every four weeks based on initial serum total IgE level or patient weight.

- A retrospective chart review of 43 chronic urticaria patients treated with omalizumab between 2006 to 2015 found that overall, 90.2% (37/41) responded within three months duration.

**Nasal Polyps**

- Administer 75 mg to 600 mg omalizumab by subcutaneous injection every two or four weeks based on initial serum total IgE level and patient weight.